Centennial Wealth Advisory LLC Purchases 31 Shares of Eli Lilly and Company $LLY

Centennial Wealth Advisory LLC lifted its position in Eli Lilly and Company (NYSE:LLY) by 9.7% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 349 shares of the company’s stock after acquiring an additional 31 shares during the period. Centennial Wealth Advisory LLC’s holdings in Eli Lilly and Company were worth $274,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. PNC Financial Services Group Inc. lifted its stake in shares of Eli Lilly and Company by 97.5% in the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock worth $83,669,349,000 after buying an additional 50,002,551 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Eli Lilly and Company by 6.7% in the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock worth $65,432,218,000 after buying an additional 4,975,395 shares in the last quarter. Wellington Management Group LLP lifted its stake in shares of Eli Lilly and Company by 0.6% in the first quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company’s stock worth $10,495,261,000 after buying an additional 81,587 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Eli Lilly and Company by 13.3% in the first quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company’s stock worth $4,808,443,000 after buying an additional 682,203 shares in the last quarter. Finally, Nuveen LLC purchased a new position in shares of Eli Lilly and Company during the first quarter valued at approximately $4,613,912,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 0.1%

Shares of LLY stock opened at $725.54 on Tuesday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $937.00. The stock has a market cap of $686.69 billion, a P/E ratio of 47.42, a P/E/G ratio of 1.01 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The company has a 50 day simple moving average of $733.42 and a two-hundred day simple moving average of $765.98.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to analysts’ expectations of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm’s revenue was up 37.6% on a year-over-year basis. During the same period in the prior year, the company earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on LLY. Wall Street Zen cut shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 20th. DZ Bank raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. Leerink Partnrs cut shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 7th. Guggenheim decreased their price objective on shares of Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating for the company in a report on Wednesday, August 13th. Finally, UBS Group decreased their price objective on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $939.61.

Insider Transactions at Eli Lilly and Company

In other news, CEO David A. Ricks acquired 1,632 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the purchase, the chief executive officer directly owned 546,601 shares in the company, valued at approximately $352,431,926.77. This trade represents a 0.30% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Daniel Skovronsky acquired 1,000 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average cost of $634.40 per share, with a total value of $634,400.00. Following the completion of the purchase, the executive vice president owned 137,660 shares of the company’s stock, valued at approximately $87,331,504. This represents a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 4,514 shares of company stock valued at $2,894,841. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.